title: Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience.
abstract: In an attempt to examine whether autologous SCT provides long-term disease control in patients with intermediate and high-risk AML where a suitable donor is not available, we analyzed the outcomes of autologous SCT in patients with intermediate and high-risk AML from 1986 to 2005. No relapses occurred after 2.2 years. The overall survival curve appears to have developed a plateau after 2.2 years. In conclusion, autologous SCT in patients with AML in whom an allogeneic transplantation is not feasible appears to be a safe alternative and a plateau in the survival curve indicates cure in a small proportion of patients.
authors.affiliation: University of Kansas Medical Center, Kansas City, KS, USA. sganguly@kumc.edu
authors.forename: Siddhartha
authors.initials: S
authors.lastname: Ganguly
authors.forename: Jaswinder
authors.initials: J
authors.lastname: Singh
authors.forename: Clint L
authors.initials: CL
authors.lastname: Divine
authors.forename: Delva
authors.initials: D
authors.lastname: Deauna-Limayo
authors.forename: David C
authors.initials: DC
authors.lastname: Bodensteiner
authors.forename: Jan L
authors.initials: JL
authors.lastname: Lewis
authors.forename: Kathy
authors.initials: K
authors.lastname: Curran
authors.forename: Barry S
authors.initials: BS
authors.lastname: Skikne
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007951:Leukemia, Myeloid / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D033581:Stem Cell Transplantation / Q000401:mortality*; D015996:Survival Rate; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous